Get the Stockscreener App
37.73
0.37%
-0.14
After Hours:
37.85
0.12
+0.32%
Cg Oncology Inc stock is traded at $37.73, with a volume of 469.81K.
It is down -0.37% in the last 24 hours and up +2.30% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$37.87
Open:
$37.34
24h Volume:
469.81K
Relative Volume:
0.66
Market Cap:
$2.53B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-69.06M
1W Performance:
-1.59%
1M Performance:
+2.30%
6M Performance:
-14.05%
1Y Performance:
+0.00%
1-Day Range:
$37.34
$39.00
1-Week Range:
$35.58
$39.00
52-Week Range:
$25.77
$50.23
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
Cg Oncology Inc Stock (CGON) Latest News
How does Cg Oncology Inc. (CGON) change from a tortoise to a hare? - SETE News
RBC Capital Mkts initates Cg Oncology Inc. (CGON) stock to an Outperform - Knox Daily
CG Oncology, Inc. (NASDAQ:CGON) Shares Sold by Perceptive Advisors LLC - MarketBeat
Ensign Peak Advisors Inc Buys New Holdings in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Wall Street SWOT: CG Oncology stock poised for growth in bladder cancer market - Investing.com
Midday Stock Roundup: Indie Shares Down 5% - Orange County Business Journal
Goldman Sachs maintains $52 target on CG Oncology shares By Investing.com - Investing.com Canada
Deerfield Management Company L.P. Series C Increases Stake in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
There is no way Cg Oncology Inc. (CGON) can keep these numbers up - SETE News
CGON: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Deeper Dive: Understanding Cg Oncology Inc. (CGON) Through its Various Ratios - The Dwinnex
Cg Oncology Inc. [CGON] Stock sold by Insider Song Hong Fang for $23.0 million - Knox Daily
RBC Capital Initiates Coverage of CG Oncology (CGON) with Outperform Recommendation - MSN
Yu Fan Makes New $49.83 Million Investment in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
CG Oncology (NASDAQ:CGON) Shares Gap Up to $39.00 - MarketBeat
CG Oncology (NASDAQ:CGON) Earns Outperform Rating from Analysts at Royal Bank of Canada - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Rhumbline Advisers - Defense World
Brokerages Set CG Oncology, Inc. (NASDAQ:CGON) PT at $64.17 - MarketBeat
Selling Buzz: Cg Oncology Inc. [CGON] Director Song Hong Fang sells 650,455 shares of the company - Knox Daily
Wilson Sonsini Advises GC Therapeutics on $65 Million Series A - Wilson Sonsini
Waterloo Capital L.P. Purchases 1,517 Shares of Copart, Inc. (NASDAQ:CPRT) - Defense World
Corning’s stock rises as it sticks to Q3 profit view - MarketWatch
Compugen Ltd. (NASDAQ:CGEN) Short Interest Update - Defense World
CGN Resources Ltd. Options Cease Amid Unmet Conditions - TipRanks
Cognyte Software (NASDAQ:CGNT) Lifted to “Strong-Buy” at StockNews.com - Defense World
Canadian General Investments (TSE:CGI) Share Price Passes Above 50 Day Moving Average of $38.48 - MarketBeat
Why is the Cochlear share price in the red today? - The Motley Fool Australia
Calamos Global Total Return Fund (NASDAQ:CGO) Short Interest Update - Defense World
Cogent Biosciences (NASDAQ:COGT) Stock Price Up 4.1% - Defense World
Adversity is less terrifying than hope: Cg Oncology Inc. (CGON) - SETE News
(CGO) Pivots Trading Plans and Risk Controls - Stock Traders Daily
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long - Business Wire
Compugen Ltd. (NASDAQ:CGEN) Short Interest Down 5.8% in August - MarketBeat
Coherus shares stumble on supply issue - The Pharma Letter
Quest Partners LLC Acquires New Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
HC Wainwright Reiterates Buy Rating for CG Oncology (NASDAQ:CGON) - MarketBeat
Analyst supports Buy rating on CG Oncology shares, focusing on differentiated safety profile - Investing.com Canada
CG Oncology, Inc. (NASDAQ:CGON) Short Interest Down 11.2% in August - MarketBeat
After-hours movers: Intuitive Machines, Casella Waste Systems, Galmed Pharma, Edgewise Therapeutics - Investing.com South Africa
Do investors need to be concerned about Cg Oncology Inc. (CGON)? - US Post News
Cogent Biosciences Inc (COGT) stock analysis: A comprehensive overview - US Post News
Coherus Biosciences Inc (CHRS) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Coherus BioSciences, Inc. (NASDAQ:CHRS) Has Found A Path To Profitability - Simply Wall St
The battle brewing over blood tests for cancer | Today News - Mint
Cg Oncology Inc. (CGON) Stock: A Comprehensive 52-Week Review - The InvestChronicle
The Battle Brewing Over Blood Tests for Cancer - The Wall Street Journal
Analyzing Cg Oncology Inc. (CGON) After Recent Trading Activity - Knox Daily
CG Oncology (NASDAQ:CGON) Trading 4.6% Higher - MarketBeat
CG Oncology surges 7%; seen benefitting from J&J bladder cancer asset data - MSN
CG Oncology, Inc. (NASDAQ:CGON) Shares Acquired by Bank of New York Mellon Corp - MarketBeat
CG Oncology surges 7%; seen benefitting from J&J bladder cancer asset data - Seeking Alpha
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):